(Q44513878)

English

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

phase II clinical trial

0 references

author name string

John Fr Robertson

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Jean-Marc Ferrero

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Hugues Bourgeois

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Hagen Kennecke

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Richard H de Boer

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

William Jacot

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Jesse McGreivy

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Samuel Suzuki

8

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Min Zhu

9

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Ian McCaffery

10

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Elwyn Loh

11

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Jennifer L Gansert

12

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Peter A Kaufman

13

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

13 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

228-235

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Letrozole in advanced breast cancer: the PO25 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin-like growth factor-I receptor signaling and resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin and insulin-like growth factor signalling in neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of mitogen-activated protein (MAP) kinase in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Disrupting insulin-like growth factor signaling as a potential cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating a treatment effect in survival studies in which patients switch treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting the phosphoinositide 3-kinase pathway in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970026-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70026-3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44513878&oldid=2026575038"